Publications

Export 72 results:
Auteur [ Title(Asc)] Type Année
Filtres: Auteur is Pedro Rosa-Neto  [Enlever les filtres]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
C
Jiang L, Oualkacha K, Didelez V, Ciampi A, Rosa-Neto P, Benedet AL, Mathotaarachchi S, Richards JBrent, Greenwood CMT.  2019.  Constrained instruments and their application to Mendelian randomization with pleiotropy.. Genet Epidemiol.
Engelborghs S, Niemantsverdriet E, Struyfs H, Blennow K, Brouns R, Comabella M, Dujmovic I, van der Flier W, Frölich L, Galimberti D et al..  2017.  Consensus guidelines for lumbar puncture in patients with neurological diseases.. Alzheimers Dement (Amst). 8:111-126.
Tam A, Dansereau C, Badhwar AP, Orban P, Belleville S, Chertkow H, Dagher A, Hanganu A, Monchi O, Rosa-Neto P et al..  2015.  Common Effects of Amnestic Mild Cognitive Impairment on Resting-State Connectivity Across Four Independent Studies.. Front Aging Neurosci. 7:242.
Chamoun M, Huppé-Gourgues F, Legault I, Rosa-Neto P, Dumbrava D, Faubert J, Vaucher E.  2017.  Cholinergic Potentiation Improves Perceptual-Cognitive Training of Healthy Young Adults in Three Dimensional Multiple Object Tracking.. Front Hum Neurosci. 11:128.
Li X, Ba M, Ng KPin, Mathotaarachchi S, Pascoal TA, Rosa-Neto P, Gauthier S.  2018.  Characterizing biomarker features of cognitively normal individuals with ventriculomegaly.. Alzheimers Dement (Amst). 10:12-21.
DuBois JM, Rousset OG, Rowley J, Porras-Betancourt M, Reader AJ, Labbe A, Massarweh G, Soucy J-P, Rosa-Neto P, Kobayashi E.  2016.  Characterization of age/sex and the regional distribution of mGluR5 availability in the healthy human brain measured by high-resolution [(11)C]ABP688 PET.. Eur J Nucl Med Mol Imaging. 43(1):152-62.
Laforce R, Rosa-Neto P, Soucy J-P, Rabinovici GD, Dubois B, Gauthier S.  2016.  Canadian Consensus Guidelines on Use of Amyloid Imaging in Canada: Update and Future Directions from the Specialized Task Force on Amyloid imaging in Canada.. Can J Neurol Sci. 43(4):503-12.
A
Liebsch F, Kulic L, Teunissen C, Shobo A, Ulku I, Engelschalt V, Hancock MA, van der Flier WM, Kunach P, Rosa-Neto P et al..  2019.  Aβ34 is a BACE1-derived degradation intermediate associated with amyloid clearance and Alzheimer's disease progression.. Nat Commun. 10(1):2240.
Gauthier S, Ng KPin, Pascoal TA, Mathotaarachchi S, Chung C-O, Benedetti AL, Shin M, Kang MSu, Li X, Ba M et al..  2017.  Author response: Neuropsychiatric symptoms predict hypometabolism in preclinical Alzheimer disease.. Neurology. 89(18):1931.
Carter SF, Herholz K, Rosa-Neto P, Pellerin L, Nordberg A, Zimmer ER.  2019.  Astrocyte Biomarkers in Alzheimer's Disease.. Trends Mol Med.
Miron J, Picard C, Lafaille-Magnan M-E, Savard M, Labonte A, Breitner JCS, Rosa-Neto P, Auld D, Poirier J.  2019.  Association of TLR4 with Alzheimer's disease risk and presymptomatic biomarkers of inflammation.. Alzheimers Dement. 15(7):951-960.
Ba M, Kong M, Li X, Ng KPin, Rosa-Neto P, Gauthier S.  2016.  Is ApoE ɛ 4 a good biomarker for amyloid pathology in late onset Alzheimer's disease? Transl Neurodegener. 5:20.
Therriault J, Ng KPin, Pascoal TA, Mathotaarachchi S, Kang MSu, Struyfs H, Shin M, Benedet AL, Walpola IC, Nair V et al..  2018.  Anosognosia predicts default mode network hypometabolism and clinical progression to dementia.. Neurology. 90(11):e932-e939.
Ongali B, Nicolakakis N, Tong X-K, Aboulkassim T, Papadopoulos P, Rosa-Neto P, Lecrux C, Imboden H, Hamel E.  2014.  Angiotensin II type 1 receptor blocker losartan prevents and rescues cerebrovascular, neuropathological and cognitive deficits in an Alzheimer's disease model.. Neurobiol Dis. 68:126-36.
Pascoal TA, Mathotaarachchi S, Mohades S, Benedet AL, Chung C-O, Shin M, Wang S, Beaudry T, Kang MS, Soucy J-P et al..  2016.  Amyloid-β and hyperphosphorylated tau synergy drives metabolic decline in preclinical Alzheimer's disease.. Mol Psychiatry.
Pascoal TA, Mathotaarachchi S, Shin M, Park AYeon, Mohades S, Benedet AL, Kang MSu, Massarweh G, Soucy J-P, Gauthier S et al..  2018.  Amyloid and tau signatures of brain metabolic decline in preclinical Alzheimer's disease.. Eur J Nucl Med Mol Imaging. 45(6):1021-1030.

Pages